Introduction
Reversible phosphorylation plays a critical role during fragmentation of Golgi apparatus (Acharya et al., 1998; Lowe et al., 1998) . Early studies show that okadaic acid induces fragmentation of the Golgi apparatus (Lucocq et al., 1991) , suggesting that enhanced serine/threonine phosphorylation of protein components are essential for this process. Using a permeabilized cell system, it has been demonstrated that MEK1 is required for fragmentation of Golgi stacks during mitosis and that ERK1 and ERK2, downstream targets of MEK1, are not necessary for this process (Acharya et al., 1998) , although tyrosine-phosphorylated ERK (pY-ERK) is associated with the Golgi complex during G 2 /M phase of the cell cycle and pY-ERK may regulate Golgi dynamics (Cha and Shapiro, 2001 ). MEK1 colocalizes with the Golgi marker giantin and it is specifically phosphorylated during mitosis, resulting in a peptide map different from that of the interphase MEK1 (Acharya et al., 1998; Colanzi et al., 2000) . It is proposed that mitotic phosphorylation induces a conformation change of MEK1 and that this mitotic form of MEK1 targets the Golgi apparatus leading to its fragmentation (Colanzi et al., 2000) . Consistently, a recent study by this group demonstrates that activated MEK1 is associated with the Golgi apparatus at late prophase but not thereafter; moreover, Raf-1, but not MEK1 kinase-1, appears to mediate MEK1-dependent fragmentation of the Golgi complex (Kee et al., 2003) . On the other hand, it has also been shown that p34 Cdc2 kinase, but not MEK1, directly regulates Golgi fragmentation by targeting the structural protein GM130 (Lowe et al., 1998) . Subsequent work by this group reveals that p34
Cdc2 phosphorylates GM130 on serine-25, which disrupts the interaction between GM130 and p115, a condition believed to be necessary for Golgi breakdown during mitosis (Lowe et al., 2000) . Moreover, GM130 is phosphorylated during prophase and dephosphorylated by protein phosphatase 2A in telophase (Lowe et al., 2000) , correlating with the fragmentation and reassembly of the Golgi apparatus, respectively. Interestingly, Golgi fragmentation induced by okadaic acid does not induce serine-25 phosphorylation of GM130 as well as its dissociation from p115 (Lowe et al., 2000) , suggesting that this phosphorylation and inactivation of p115 may be mitotic specific or that p34
Cdc2 -mediated phosphorylation of serine-25 and subsequent events may only play a partial role in the initiation of Golgi breakdown. Using an in vitro reconstitution system, it has been demonstrated that both MEK and Cdc2 are involved in Golgi breakdown that consists of two morphologically distinguishable processes (Kano et al., 2000) . Whereas MEK is primarily responsible for the first process when Golgi stacks break into punctate structures, Cdc2 mainly regulates the second process when fragmented Golgi intermediates further breakdown and translocate to ER (Kano et al., 2000) .
It has also been reported that Polo-like kinase (Plk1) participates in the regulation of Golgi fragmentation during mitosis (Lin et al., 2000; Sutterlin et al., 2001 ). Plk1 interacts with and phosphorylates GRASP65, a Golgi-associated protein, and the carboxyl-terminus of Plk1 is important in the phosphorylation of GRASP65 (Lin et al., 2000) . In addition, downregulation of Plk1 activity by either the addition of kinase-defective Plk1 or by immunodepletion greatly diminishes Golgi fragmentation in vitro (Sutterlin et al., 2001) , suggesting that the phosphorylation of GRASP65 by Plk1 may be an essential event in Golgi inheritance during mitosis.
We have recently shown that Plk3, a distinct member of polo family kinases in mammals, colocalized with the Golgi apparatus during the cell cycle and that ectopic expression of Plk3, but not kinase-defective Plk3, significantly induced fragmentation of Golgi stacks (Ruan et al., 2003) . Our current studies strongly suggest that Plk3 may be a downstream mediator of MEK1 in the signaling cascade leading to Golgi fragmentation.
Results
We have recently demonstrated that Plk3 is Golgilocalized during the cell cycle and ectopic expression of Plk3, but not the kinase-defective Plk3 K52R , results in significant Golgi breakdown (Ruan et al., 2004) . Consistent with our early studies (Ruan et al., 2004) , the antibody to Plk3 was specific and recognized only one band on Western blots in HeLa cell lysates ( Figure 1a ). Ectopic expression of a Plk3 construct, but not the vehicle, resulted in significant enrichment of Plk3 antigen (Figure 1a) . In interphase HeLa cells, a low level of Plk3 was detected throughout the cell; however, Plk3 was concentrated at the Golgi apparatus as revealed by costaining with giantin, a Golgi-specific protein (Figure 1b) . During mitosis, although Plk3 signals redistributed in a manner similar to those of fragmented Golgi, significant amounts of Plk3 was also found around the spindle poles (Figure 1b) .
MEK1 (Acharya et al., 1998) and tyrosine-phosphorylated ERK1 (Cha and Shapiro, 2001 ) are involved in regulating Golgi dynamics. A recent study shows that a fraction of activated MEK1 is translocated to Golgi during late prophase (Colanzi et al., 2003) . Given that active MAP kinase members are localized to spindle poles and/or kinetochores during mitosis (Beauvais et al., 1995; Yu et al., 1997) and that Plk3 has a centrosomal localization (Wang et al., 2002) , we costained HeLa cells with antibodies to Plk3 and phosphorylated (activated) MEKs (p-MEKs). Interestingly, while no significant signal was detected in interphase cells (not shown) p-MEK-specific signals were strong during mitosis (Figure 2a) . The p-MEK signal was found at the spindle poles during prophase (not shown) and metaphase (Figure 2a) , colocalizing with Plk3 signals. Whereas Plk3 remained detectable at spindle pole and the regions close to the midbody during telophase p-MEK staining was absent from the spindle pole (Figure 2a) . Instead, p-MEK signals were very strong at the midbody during mitotic exit. Concentrated phospho-ERK signals were also detected at spindle poles during metaphase (Figure 2b ) as well as other mitotic stages (data not shown), colocalizing with Plk3.
The close proximity of Plk3 and activated MEKs and ERKs during early mitosis prompted us to study their physical association. Pull-down assays showed that Plk3 resin, but not the control resin, precipitated MEK1 (Figure 2c) , consistent with the reported role of MEK1 in the regulation of Golgi breakdown during the onset of mitosis (Acharya et al., 1998) . Plk3 resin also specifically precipitated ERK2 protein (Figure 2c ). Quantitative analysis showed that about 2% of total MEK1 or ERK2 were associated with Plk3 during the pull-down assays. It remains unknown whether Plk3 directly interacted with both MEK1 and ERK2 or with only one of them because MEKs and ERKs are known to interact with each other. The physical association between Plk3 and MEK1/ ERK2 suggests that Plk3 may lie in the same pathway as MEK1/ERK2 that regulates Golgi fragmentation and dispersal. To study the hierarchy of Plk3 and MEK1 in the regulation of Golgi fragmentation, we treated HeLa cells with U0126 and PD98059, two MEK-specific inhibitors, and then asked whether the activation of Plk3 by nocodazole was affected. Whereas nocodazole rapidly activated Plk3 ( Figure 3A) , pretreatment of cells with either U0126 or PD98059 prevented Plk3 from activation by nocodazole, suggesting that MEKs lies upstream of Plk3 in the regulatory cascade. In vitro kinase assays showed ( Figure 3b ) that neither U0126 nor PD98059 (data not shown) directly affected Plk3 kinase activity towards a-casein at the concentration used in vivo.
Golgi stacks breakdown when cells enter mitosis ( Figure 1a ) or express transfected Plk3 (Ruan et al., 2004) . To study the effect of MEK inhibitors on Plk3-induced fragmentation, HeLa cells transfected with Plk3 expression plasmid construct, or with the vector alone, were cultured in the medium containing PD98059, U0126 or the vehicle (DMSO). Cells expressing transfected Plk3 were revealed by staining with antibody to Plk3 (red-staining). Plk3-expressing cells, as well as cells expressing no transfected Plk3, were examined for Golgi breakdown via immunofluorescent microscopy. Compared with those control cells that had an intact Golgi apparatus, the vehicle did not have a significant effect on Figure 2 Colocalization and physical interaction of Plk3 with activated MEK1 and ERKs during early mitosis. (a) HeLa cells were fixed and stained with antibodies to Plk3 (red) and to phosphorylated MEK1 (p-MEK1, green). DNA was stained with DAPI (blue). Representative cells of metaphase and telophase were shown. Bar, 5 mm. (b) HeLa cells were fixed and stained with an antibody to Plk3 (red) and to phosphorylated ERKs (green). DNA was stained with DAPI (blue). A representative metaphase cell was shown. Bar, 5 mm. (c) Recombinant His 6 -Plk3 was expressed in Sf-9 cells using a baculoviral vector expression system and purified through affinity chromatography. Plk3 resin, or the resin alone as the control, was incubated with HeLa cell lysates (0.5 mg). After thorough wash, proteins interacting with Plk3 resin (with duplicates) or the resin alone were analysed by SDS-PAGE followed by immunoblotting using the antibodies to MEK1 and to ERKs. HeLa cell lysates (50 mg) were also loaded as the control. Data were representative of three independent experiments
Figure 3 MEK1-specific inhibitors block both activation of Plk3 by nocodazole. (a) HeLa cells were pretreated with U0126 or PD98059 for 1 h before the addition of nocodazole or DMSO. After treatment with nocodazole for 30 min or 2 h, cell lysates were prepared. An equal amount of lysates was immunoprecipitated with the antibody to Plk3. Immunoprecipitates were assayed for kinase activity using a-casein as substrate. Recombinant Plk3 (lane 12) was used as a positive control for the kinase assay. Immunoprecipitation efficiency was monitored by immunoblotting of the precipitates using Plk3 antibody. Recombinant Plk3 used was smaller than the endogenous one due to a shorter N-terminal deletion. (a) Purified His 6 -Plk3 was assayed for its kinase activity in vitro in the presence or absence of U0126
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Golgi fragmentation induced by ectopic expression of Plk3 (Figure 4a , arrows). However, PD98059 markedly blocked Plk3-induced Golgi breakdown (Figure 4a and c). A similar inhibition of Plk3-induced Golgi fragmentation was also observed in cells treated with U0126 (Figure 4a and 4c) . These results suggest that transfected Plk3, even though expressed at relatively high levels, may require the activation by upstream regulators in vivo.
To further test whether Plk3 is downstream of MEK1 in the Golgi fragmentation cascade, we transfected HeLa cells either with a plasmid construct expressing activated MEK1 (MEK1-A) (Zheng et al., 1994) or with the vector alone. Transfected MEK1-A was efficiently expressed and migrated slightly faster than the endogenous one, and a short-term treatment with nocodazole did not significantly modulate their expression levels ( Figure 5a ). Ectopic expression of MEK1-A somehow decreased the endogenous MEK1 level. Immunocomplex kinase assays revealed (Figure 5b Consistent with the known function of MEK1 in Golgi dynamics (Acharya et al., 1998) , ectopic expression of MEK1-A, but not the kinase-defective MEK1 K97R , for 20 h stimulated significant Golgi breakdown (Figure 5c ). To confirm the role of MEK1 in mediating Plk3-induced Golgi breakdown, we cotransfected HeLa cells with various combinations of plasmid constructs expressing MEK1-A, Plk3 and kinase-defective versions of these two enzymes for 12 h. Cells expressing Plk3 or Plk3 K52R were examined for their Golgi fragmentation. A short transfection time (12 h) was designed to lower the percentage of cells expressing MEK1 or Plk3 and with Golgi fragmentation. We observed (Figure 5d ) that MEK1-A stimulated Plk3-induced Golgi breakdown, whereas MEK1 K97R did not significantly affect Golgi fragmentation induced by Plk3. Moreover, MEK1-A did not stimulate any Golgi fragmentation in cells expressing Plk3
K52R
, again indicating that Plk3 lies downstream of MEK1 in the signaling cascade leading to Golgi fragmentation. The expression of transfected MEK1-A or MEK1 K97R in HeLa cells was confirmed by both Western blotting and immunofluorescent microscopy (data not shown).
Plk3 is involved in the regulation of mitotic functions (Ouyang et al., 1997) and ectopic expression of Plk3 results in the breakdown of the Golgi apparatus (Ruan et al., 2004) , strongly suggesting a role of this kinase in the regulation of Golgi fragmentation during the cell cycle. To further confirm the role of Plk3 in Golgi dynamics in vivo, we made use of PLK3 mutant mice that were just available in the laboratory. Murine embryonic fibroblast (MEF) cells were established from day 14.5 embryos. Genotyping of MEFs was achieved via polymerase chain reaction using primers that were capable of discriminating the wild-type allele from the mutant-type one. The results were shown in Figure 6a . PLK3 À/À MEFs, as well as wild-type MEFs, were then treated with nocodazole (0.4 mg/ml) for 45 min and cells with fragmented Golgi apparatus were scored via immunofluorescent microscopy. We demonstrated that PLK3 ablation significantly slowed down the The plasmid construct expressing kinase-defective Plk3 (Plk3 K52R ) was also used for transfection as the control. Cells ectopically expressing transfected Plk3 were revealed by staining with antibodies to Plk3 (red) and giantin (green). DNA was stained with DAPI (blue). Endogenous Plk3 staining was not visible due to imaging settings designed for capturing high levels of transfected Plk3. However, giantin signals reflecting intact Golgi apparatus in these interphase cells were easily visible. Representative cells of each treatment were shown. Bar, 10 mm. (b) HeLa cells transfected with a construct expressing active Plk3 (Plk3-A) were lysed. Equal amounts (50 mg) of cell lysates were blotted for Plk3. Transfected Plk3-A was smaller than the endogenous one due to a shorter Nterminal deletion. (c) HeLa cells ectopically expressing transfected Plk3-A in the presence of MEK1 inhibitors or the vehicle were examined for their Golgi fragmentation. At least two hundred cells expressing transfected Plk3 from each treatment were examined. Data represents the average of three independent experiments MEK1, Plk3 and the Golgi dynamics S Xie et al breakdown of Golgi upon nocodazole treatment (Figure 6b ), indicating that Plk3 does play a role in the dynamics of Golgi apparatus during cell division. Based on our current studies as well as on evidence in literature, a simple model as shown in Figure 7 is proposed to illustrate the molecular pathway leading to Golgi breakdown in certain stress situations as well as during mitosis as our early studies show that Plk3 affects microtubule dynamics during the cell cycle (Zheng and Guan, 1994). MEK1 integrates both intrinsic mitotic signals and external stress signals such as microtubule disruption and passes them to an MAP kinase family member (e.g. ERK2), which may in turn activate Plk3 directly or indirectly. Activated Plk3 targets a Golgispecific structural protein(s), resulting in initial fragmentation of this organelle. Other protein kinases such as p34
Cdc2 and/or Plk1 are likely to target additional Golgi proteins leading to further breakdown of the Golgi apparatus.
Discussion
Our current studies further support a role of Plk3 in Golgi fragmentation signaling cascade because Plk3-null MEF cells exhibited some abnormalities in Golgi breakdown ( Figure 6 ). Our studies also support the role of MEK1 in regulating Golgi dynamics during the cell cycle. Plk3 appears to be a downstream mediator of MEK1 in the signaling pathway leading to Golgi fragmentation and dispersal. MEK-specific inhibitors block the activation of Plk3 by nocodazole ( Figure 3a ) and inhibit Plk3-induced Golgi fragmentation (Figure 4) . Consistently, ectopic expression of activated MEK1 results in constitutive activation of Plk3 (Figure 5a and b). Furthermore, activated MEK1 fails to stimulate Golgi fragmentation in cells expressing Plk3 K52R , whereas it augments Plk3-induced Golgi breakdown ( Figure 5D ). However, the strict substrate specificity of MEK1 renders Plk3 an unlikely target, which is supported by our preliminary observation that MEK1 does not activate Plk3 in vitro (data not shown). On the other hand, Plk3 could be a direct target of MAP kinase family members, and thus the observed interaction between MEK1 and Plk3 could be indirect. The latter scenario is consistent with several early studies: (i) ERK2 phosphorylates GRASP55 on the same sites that constitute MPM2 phospho-epitopes (Jesch et al., 2001) ; (ii) tyrosine-phosphorylated ERK is associated with the newly formed Golgi apparatus in late mitosis and increased ERK phosphorylation causes apparent Golgi breakdown (Cha and Shapiro, 2001 ); (iii) nocodazole rapidly activates Plk3 (Ruan et al., 2004) as well as MEK1 (unpublished data). The possibility that Plk3 may be a direct target of an MAP kinase is further supported by our observations reported in this study. Plk3 colocalizes with phospho-ERKs (Figure 2b ) at spindle poles during mitosis. Moreover, ERK2 physically interacts with Plk3 (Figure 2c ).
Plk3-induced Golgi fragmentation requires the activation by upstream regulators because MEK1 inhibitors are capable of blocking endogenous Plk3 activation as well as Golgi breakdown in cells expressing transfected Plk3. These observations would also suggest that Golgi fragmentation induced by expressed Plk3 mimics a cellular process and that overexpressed Plk3 does not significantly, if any, tie up factors (e.g. inhibitors) for Golgi fragmentation in vivo. Actually, overexpression of Plk3 K52R at a level similar to that of Plk3 does not induce significant Golgi fragmentation (Ruan et al., 2004) . As phospho-MEKs, phospho-ERKs and Plk3 are all localized to spindle poles during early mitosis, activated MEK1 could be essential for the maintenance of the activities of ERK2 and Plk3, both of which participate in the regulation of Golgi fragmentation. Extensive breakdown of Golgi ensures even dispersal and partitioning of this organelle during mitosis. After metaphase, fragmented Golgi vesicles that have been largely partitioned begin to reassemble, which correlates with the disappearance of phosphorylated MEK1 at spindle poles during mitotic exit.
It has been reported that MEK and Cdc2 are, respectively, involved in two sequential and morphologically distinguishable processes that mediate Golgi breakdown during mitosis (Kano et al., 2000) . MEK is proposed to be primarily involved in the first process when Golgi stacks break into punctate structures (Kano et al., 2000) , the morphology of which is similar to the fragmented Golgi shortly after nocodazole treatment (Ruan et al., 2004) . Plk3-induced breakdown of Golgi apparatus somewhat resembles the first process (Ruan et al., 2004) (Figure 4a ), also consistent with the notion that Plk3 may lie in the same signaling pathway as MEK1. We have previously shown that Plk3 may affect microtubule dynamics (Wang et al., 2002) . Microtubule integrity inevitably plays an essential role in Golgi breakdown during the cell cycle. Given that mitosis accompanies drastic microtubule remodeling as well as cell rounding, it is likely that certain microtubule stresses may accelerate the onset of mitosis. Our current model proposes that MEK1 may be a key integrator for both intrinsic (e.g. mitosis) and external (microtubule stresses) signals that lead to Golgi fragmentation, a prerequisite for the onset of mitosis (Sutterlin et al., 2002) . Additional protein kinases such as p34
Cdc2 and Plk1 are also involved in the phosphorylation of Golgi targets, resulting in complete mitotic disassembly that yields extensively fragmented, fine clusters of the Golgi apparatus.
Materials and methods

Cell culture and treatment
HeLa cell line was obtained from American Type Culture Collection (ATCC). Cells were cultured in culture dishes or on Lab-Tek II chamber slides (Fisher Scientific) in appropriate media supplemented with 10% fetal bovine serum (FBS) and antibiotics (100 mg/ml penicillin and 50 mg/ml streptomycin sulfate) with 5% CO 2 . To study the effect of MEK1 inhibitors on the activation of Plk3, HeLa cells were preincubated in culture medium containing either PD98059 (40 mM) or U0126 (40 mM) or with vehicle (DMSO) as controls for 1 h before the initiation of nocodazole (0.4 mg/ml) treatment. Cells were collected at various times (30 min or 2 h) after nocodazole 
Kinase assays
Immunocomplex kinase assays were performed essentially as described (Ouyang et al., 1997) . In brief, HeLa cells treated with nocodazole in the presence or absence of an MEK1 inhibitor were lysed for various times. An equal amount of cell lysates (0.5 mg) was subjected to immunoprecipitation with antibodies to Plk3. The resulting precipitates were resuspended in a kinase buffer (10 mM HEPES-NaOH (pH 7.4), 10 mM MnCl 2 , 5 mM MgCl 2 , 10 mM ATP). The kinase reaction was initiated by the addition of [g-32 P]ATP (2 mCi) (Amersham Pharmacia Biotech) and a-casein (Sigma). Recombinant His 6 -Plk3 was also assayed for kinase activity as controls. After incubation for 30 min at 371C, the reaction mixtures were analysed by SDS-PAGE followed by immunoblotting for Plk3 and by autoradiography for phospho-a-casein.
Pull-down assays and immunoblotting
Recombinant His 6 -Plk3 expressed with the use of a baculoviral expression system as described (Ouyang et al., 1999) was affinity purified with and subsequently conjugated to Ni-NTA resin (Qiagen). The His 6 -Plk3 resin and the control resin were incubated with protein lysates (1 mg) from HeLa cells with gentle rocking. After centrifugation, the resin was rinsed five times with the cell lysis buffer and the proteins interacting with the resin were analysed by SDS-PAGE followed by Western blotting using antibodies against MEKs and ERKs (Cell Signaling). Specific signals were detected with horseradish peroxidase-conjugated goat-anti-rabbit secondary antibodies and enhanced chemiluminescence reagents (Pierce).
Fluorescence microscopy
Colocalization of Plk3 with phospho-MEKs or phosphoERKs was determined by double immunofluorescence analysis. Cells were quickly washed with phosphate-buffered saline (PBS) and fixed in methanol for 5 min at room temperature. Fixed cells were treated with 0.1% Triton X-100 in PBS for 10 min on ice, and then washed three times with ice-cold PBS. After blocking with 2.0% bovine serum albumin (BSA) in PBS for 15 min at room temperature, cells were incubated for 1 h with mouse monoclonal Plk3 immunoglobulin G (IgG, 4 mg/ ml) and rabbit anti-phospho-MEK, or anti-phospho-ERK, IgGs, (Cell Signaling), in 2% BSA solution, washed with PBS and then incubated with Rodamine-Red-X-conjugated with anti-mouse IgGs and/or fluorescein isothiocyanate-conjugated anti-rabbit IgGs (Jackson Immuno Research) at room temperature for 1 h in the dark. In some experiments, cells were finally stained with DAPI (Fluka, 1 mg/ml) for 5 min. Fluorescence microscopy was performed on a Nikon microscope and images were captured using a digital camera (Optronics) using Optronics MagFire, Image-Pro Plus softwares. Golgi fragmentation in Plk3-null MEF and wild-type MEF cells was examined and scored by counting at least two hundreds of cells in each experiment. Statistical significance of difference in the rate of Golgi fragmentation between these two groups was determined using the Student's t-test.
Transfection
HeLa cells cultured in dishes or on chamber slides were transfected, using the lipofectamine method, with plasmid constructs expressing for Plk3, Plk3 K52R , activated MEK1 and/ or MEK1 K97R for either 12 or 20 h. Untransfected control cells as well as the transfected cells were then processed for immunofluorescence microscopy. In some experiments, transfected cells were lysed and equal amounts of proteins were subjected to either immunoblotting analysis for MEK1 antigen or immunoprecipitation using Plk3 antibody. The Plk3 immunoprecipitates were assayed for in vitro kinase activity. The Plk3 K52R was obtained by replacing the conserved lysine-52 residue with arginine; the resulting protein was kinase defective (Ouyang et al., 1999) . The activated MEK1 and MEK1
K97R
were as described (Zheng and Guan, 1994; Mansour et al., 1996) . Each transfection experiment was repeated for at least three times.
Genotyping of Plk3 mutant MEF cells
The PLK3 mutant mice were generated in collaboration with Lexicon Genetics by a gene trapping method (Zambrowicz et al., 1998) . Genomic DNA from MEF cells was genotyped with a PCR approach. The nucleotide sequences of the PCR primers were as follows: forward primer A, 5 0 -TGCCAGTGGGCTGAGGGTATA-3 0 ; forward primer LTR, 5 0 -AAATGGCGTTACTTAAGCTAGCTTGC-3 0 ; and reverse primer B, 5 0 -ATCTCCACTGCTGGCCAGTGT-3 0 . Genomic DNA was subjected to PCR amplification with primers LTR, A, and B. The amplification protocol comprised an initial denaturation at 941C for 8 min; 35 cycles of 941C for 45 s, 551C for 30 s and 721C for 1 min; and a final extension at 721C for 10 min. PCR products were fractionated by electrophoresis on a 1% agarose gel and detected by ethidium bromide staining. Primers A and B detected the wild-type PLK3 allele and LTR and primer B detected the mutated allele.
